Rankings
▼
Calendar
LGND Q2 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$85M
+104.4% YoY
Gross Profit
$54M
63.9% margin
Operating Income
$46M
54.0% margin
Net Income
$31M
36.3% margin
EPS (Diluted)
$1.79
QoQ Revenue Growth
+53.5%
Cash Flow
Operating Cash Flow
$20M
Free Cash Flow
$16M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$470M
Stockholders' Equity
$787M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$85M
$41M
+104.4%
Gross Profit
$54M
$34M
+60.1%
Operating Income
$46M
$7M
+544.2%
Net Income
$31M
$22M
+39.1%
Revenue Segments
Material Sales, Captisol
$63M
59%
Contract Revenue
$14M
13%
Royalty
$9M
8%
Contract Revenue, Service
$7M
7%
Kyprolis
$5M
5%
Milestone
$4M
3%
Evomela
$2M
2%
License Fees, Milestones, and Product, Other, Product, Other
$2M
1%
License Fees
$1M
1%
Royalty, Other
$983,000
1%
← FY 2021
All Quarters
Q3 2021 →